Structural, biological, and pharmacological strategies for the inhibition of nerve growth factor

Neurochemistry International

Volumn 61, Issue 8, 2012, Pages 1266-1275

  Eibl, Joseph K ^a   Strasser, Bridget C ^a   Ross, Gregory M ^a  

^a NORTHERN ONTARIO SCHOOL OF MEDICINE   (Canada)

Author keywords

Antagonist; Neurotrophin; NGF; p75; Tanezumab; TrkA

Indexed keywords

HYBRID PROTEIN; K 252A; KYNURENIC ACID; METAL ION; NERVE GROWTH FACTOR; NERVE GROWTH FACTOR RECEPTOR; NEUROTROPHIN; NEUROTROPHIN RECEPTOR P75; NONSTEROID ANTIINFLAMMATORY AGENT; PROTEIN TYROSINE KINASE A; ZINC;

ARTICLE; CHRONIC PAIN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION;

EID: 84870295768     PISSN: 01970186     EISSN: 18729754     Source Type: Journal    
DOI: 10.1016/j.neuint.2012.10.008     Document Type: Short Survey

References (78)

1. Y.N. Abdiche, D.S. Malashock, and J. Pons Probing the binding mechanism and affinity of Tanezumab, a recombinant humanized anti-NGF monoclonal antibody, using a repertoire of biosensors Protein Sci. 17 2008 1326 1335
2. C. Allington, I.L. Shamovsky, G.M. Ross, and R.J. Riopelle Zinc inhibits p75NTR-mediated apoptosis in chick neural retina Cell Death Differ. 8 2001 451 456
3. S.C. Apfel Nerve growth factor for the treatment of diabetic neuropathy: what went wrong, what went right, and what does the future hold? Int. Rev. Neurobiol. 50 2002 393 413
4. D.W. Banner, A. D'Arcy, W. Janes, R. Gentz, H.J. Schoenfeld, C. Broger, H. Loetscher, and W. Lesslauer Crystal structure of the soluble human 55 kd TNF receptor-human TNF beta complex: implications for TNF receptor activation Cell 73 1993 431 445
5. P.A. Barker High affinity not in the vicinity? Neuron 53 2007 1 4
6. P.A. Barker, and E.M. Shooter Disruption of NGF binding to the low affinity neurotrophin receptor p75LNTR reduces NGF binding to TrkA on PC12 cells Neuron 13 1994 203 215
7. N. Beglova, L. LeSauteur, I. Ekiel, H.U. Saragovi, and K. Gehring Solution structure and internal motion of a bioactive peptide derived from nerve growth factor J. Biol. Chem. 273 1998 23652 23658
8. M.M. Berg, D.W. Sternberg, B.L. Hempstead, and M.V. Chao The low-affinity p75 nerve growth factor (NGF) receptor mediates NGF-induced tyrosine phosphorylation Proc. Natl. Acad. Sci. USA 88 1991 7106 7110
9. M. Bibel, E. Hoppe, and Y.A. Barde Biochemical and functional interactions between the neurotrophin receptors trk and p75NTR EMBO J. 18 1999 616 622
10. F. Brahimi, J. Liu, A. Malakhov, S. Chowdhury, E.O. Purisima, L. Ivanisevic, A. Caron, K. Burgess, and H.U. Saragovi A monovalent agonist of TrkA tyrosine kinase receptors can be converted into a bivalent antagonist Biochim. Biophys. Acta 1800 2010 1018 1026
11. M.J. Butte, P.K. Hwang, W.C. Mobley, and R.J. Fletterick Crystal structure of neurotrophin-3 homodimer shows distinct regions are used to bind its receptors Biochemistry 37 1998 16846 16852
12. A. Cattaneo Tanezumab, a recombinant humanized mAb against nerve growth factor for the treatment of acute and chronic pain Curr. Opin. Mol. Ther. 12 2010 94 106
13. M.V. Chao, R. Rajagopal, and F.S. Lee Neurotrophin signalling in health and disease Clin. Sci. (Lond.) 110 2006 167 173
14. A. Colquhoun, G.M. Lawrance, I.L. Shamovsky, R.J. Riopelle, and G.M. Ross Differential activity of the nerve growth factor (NGF) antagonist PD90780 [7-(benzolylamino)-4,9-dihydro-4-methyl-9-oxo-pyrazolo[5,1-b] quinazoline-2-carboxylic acid] suggests altered NGF-p75NTR interactions in the presence of TrkA J. Pharmacol. Exp. Ther. 310 2004 505 511
15. S. Covaceuszach, A. Cassetta, P.V. Konarev, S. Gonfloni, R. Rudolph, D.I. Svergun, D. Lamba, and A. Cattaneo Dissecting NGF interactions with TrkA and p75 receptors by structural and functional studies of an anti-NGF neutralizing antibody J. Mol. Biol. 381 2008 881 896
16. G. Dechant, and Y.A. Barde The neurotrophin receptor p75(NTR): novel functions and implications for diseases of the nervous system Nat. Neurosci. 5 2002 1131 1136
17. C.D. Deppmann, S. Mihalas, N. Sharma, B.E. Lonze, E. Niebur, and D.D. Ginty A model for neuronal competition during development Science 320 2008 369 373
18. A. Dray Neuropathic pain: emerging treatments Br. J. Anaesth. 101 2008 48 58
19. J.K. Eibl, S.A. Chapelsky, and G.M. Ross Multipotent neurotrophin antagonist targets brain-derived neurotrophic factor and nerve growth factor J. Pharmacol. Exp. Ther. 332 2010 446 454
20. D. Esposito, P. Patel, R.M. Stephens, P. Perez, M.V. Chao, D.R. Kaplan, and B.L. Hempstead The cytoplasmic and transmembrane domains of the p75 and Trk A receptors regulate high affinity binding to nerve growth factor J. Biol. Chem. 276 2001 32687 32695
21. M. Fahnestock, G. Yu, and M.D. Coughlin ProNGF: a neurotrophic or an apoptotic molecule? Prog. Brain Res. 146 2004 101 110
22. F. Fant, W.F. Vranken, and F.A. Borremans The three-dimensional solution structure of Aesculus hippocastanum antimicrobial protein 1 determined by 1H nuclear magnetic resonance Proteins 37 1999 388 403
23. D. Feng, T. Kim, E. Ozkan, M. Light, R. Torkin, K.K. Teng, B.L. Hempstead, and K.C. Garcia Molecular and structural insight into proNGF engagement of p75NTR and sortilin J. Mol. Biol. 396 2010 967 984
24. K. Garber Fate of novel painkiller mAbs hangs in balance Nat. Biotechnol. 29 2011 173 174
25. J.J. Gentry, P.A. Barker, and B.D. Carter The p75 neurotrophin receptor: multiple interactors and numerous functions Prog. Brain Res. 146 2004 25 39
26. Y. Gong, P. Cao, H.J. Yu, and T. Jiang Crystal structure of the neurotrophin-3 and p75NTR symmetrical complex Nature 454 2008 789 793
27. X.L. He, and K.C. Garcia Structure of nerve growth factor complexed with the shared neurotrophin receptor p75 Science 304 2004 870 875
28. F.F. Hefti, A. Rosenthal, P.A. Walicke, S. Wyatt, G. Vergara, D.L. Shelton, and A.M. Davies Novel class of pain drugs based on antagonism of NGF Trends Pharmacol. Sci. 27 2006 85 91
29. B.L. Hempstead Commentary: Regulating proNGF action: multiple targets for therapeutic intervention Neurotox. Res. 16 2009 255 260
30. B.L. Hempstead, D. Martin-Zanca, D.R. Kaplan, L.F. Parada, and M.V. Chao High-affinity NGF binding requires coexpression of the trk proto-oncogene and the low-affinity NGF receptor Nature 350 1991 678 683
31. E.M. Hoffman, Z. Zhang, M.B. Anderson, R. Schechter, and K.E. Miller Potential mechanisms for hypoalgesia induced by anti-nerve growth factor immunoglobulin are identified using autoimmune nerve growth factor deprivation Neuroscience 193 2011 452 465
32. D.R. Holland, L.S. Cousens, W. Meng, and B.W. Matthews Nerve growth factor in different crystal forms displays structural flexibility and reveals zinc binding sites J. Mol. Biol. 239 1994 385 400
33. D. Holmes Anti-NGF painkillers back on track? Nat. Rev. Drug Discov. 11 2012 337 338
34. Y. Indo Genetics of congenital insensitivity to pain with anhidrosis (CIPA) or hereditary sensory and autonomic neuropathy type IV. Clinical, biological and molecular aspects of mutations in TRKA(NTRK1) gene encoding the receptor tyrosine kinase for nerve growth factor Clin. Auton. Res. 12 Suppl. 1 2002 I20 I32
35. Y. Indo Nerve growth factor, interoception, and sympathetic neuron: lesson from congenital insensitivity to pain with anhidrosis Auton. Neurosci. 147 2009 3 8
36. Y. Indo, M. Tsuruta, Y. Hayashida, M.A. Karim, K. Ohta, T. Kawano, H. Mitsubuchi, H. Tonoki, Y. Awaya, and I. Matsuda Mutations in the TRKA/NGF receptor gene in patients with congenital insensitivity to pain with anhidrosis Nat. Genet. 13 1996 485 488
37. J.C. Jaen, E. Laborde, R.A. Bucsh, B.W. Caprathe, R.J. Sorenson, J. Fergus, K. Spiegel, J. Marks, M.R. Dickerson, and R.E. Davis Kynurenic acid derivatives inhibit the binding of nerve growth factor (NGF) to the low-affinity p75 NGF receptor J. Med. Chem. 38 1995 4439 4445
38. N.E. Lane, T.J. Schnitzer, C.A. Birbara, M. Mokhtarani, D.L. Shelton, M.D. Smith, and M.T. Brown Tanezumab for the treatment of pain from osteoarthritis of the knee N. Engl. J. Med. 363 2010 1521 1531
39. F. Lebrun-Julien, B. Morquette, A. Douillette, H.U. Saragovi, and A. Di Polo Inhibition of p75(NTR) in glia potentiates TrkA-mediated survival of injured retinal ganglion cells Mol. Cell. Neurosci. 40 2009 410 420
40. H.B. Lee, M.C. Zaccaro, M. Pattarawarapan, S. Roy, H.U. Saragovi, and K. Burgess Syntheses and activities of new C10 beta-turn peptidomimetics J. Org. Chem. 69 2004 701 713
41. R. Lee, P. Kermani, K.K. Teng, and B.L. Hempstead Regulation of cell survival by secreted proneurotrophins Science 294 2001 1945 1948
42. L. LeSauteur, L. Wei, B.F. Gibbs, and H.U. Saragovi Small peptide mimics of nerve growth factor bind TrkA receptors and affect biological responses J. Biol. Chem. 270 1995 6564 6569
43. B. Lu Pro-region of neurotrophins: role in synaptic modulation Neuron 39 2003 735 738
44. B. Lu, P.T. Pang, and N.H. Woo The yin and yang of neurotrophin action Nat. Rev. Neurosci. 6 2005 603 614
45. S. Mahapatra, H. Mehta, S.B. Woo, and K.E. Neet Identification of critical residues within the conserved and specificity patches of nerve growth factor leading to survival or differentiation J. Biol. Chem. 284 2009 33600 33613
46. R.N. Maini, P.C. Taylor, E. Paleolog, P. Charles, S. Ballara, F.M. Brennan, and M. Feldmann Anti-tumour necrosis factor specific antibody (infliximab) treatment provides insights into the pathophysiology of rheumatoid arthritis Ann. Rheum. Dis. 58 Suppl. 1 1999 I56 60
47. R. Maitra, I.L. Shamovsky, W. Wang, M. Solc, G. Lawrance, S.M. Dostaler, G.M. Ross, and R.J. Riopelle Differential effects of transition metal cations on the conformation and biological activities of nerve growth factor Neurotox Res 2 2000 311 320
48. P.W. Mantyh, M. Koltzenburg, L.M. Mendell, L. Tive, and D.L. Shelton Antagonism of nerve growth factor-TrkA signaling and the relief of pain Anesthesiology 115 2011 189 204
49. D.R. Marsh, S.T. Wong, S.O. Meakin, J.I. MacDonald, E.F. Hamilton, and L.C. Weaver Neutralizing intraspinal nerve growth factor with a trkA-IgG fusion protein blocks the development of autonomic dysreflexia in a clip-compression model of spinal cord injury J. Neurotrauma 19 2002 1531 1541
50. S.M. Massa, Y. Xie, T. Yang, A.W. Harrington, M.L. Kim, S.O. Yoon, R. Kraemer, L.A. Moore, B.L. Hempstead, and F.M. Longo Small, nonpeptide p75NTR ligands induce survival signaling and inhibit proNGF-induced death J. Neurosci. 26 2006 5288 5300
51. S.M. Massa, T. Yang, Y. Xie, J. Shi, M. Bilgen, J.N. Joyce, D. Nehama, J. Rajadas, and F.M. Longo Small molecule BDNF mimetics activate TrkB signaling and prevent neuronal degeneration in rodents J. Clin. Invest. 120 2010 1774 1785
52. N.Q. McDonald, R. Lapatto, J. Murray-Rust, J. Gunning, A. Wlodawer, and T.L. Blundell New protein fold revealed by a 2.3-A resolution crystal structure of nerve growth factor Nature 354 1991 411 414
53. S.B. McMahon, D.L. Bennett, J.V. Priestley, and D.L. Shelton The biological effects of endogenous nerve growth factor on adult sensory neurons revealed by a trkA-IgG fusion molecule Nat. Med. 1 1995 774 780
54. O. Niederhauser, M. Mangold, R. Schubenel, E.A. Kusznir, D. Schmidt, and C. Hertel NGF ligand alters NGF signaling via p75(NTR) and trkA J. Neurosci. Res. 61 2000 263 272
55. J.B. Owolabi, G. Rizkalla, A. Tehim, G.M. Ross, R.J. Riopelle, R. Kamboj, M. Ossipov, D. Bian, S. Wegert, F. Porreca, and D.K. Lee Characterization of antiallodynic actions of ALE-0540, a novel nerve growth factor receptor antagonist, in the rat J. Pharmacol. Exp. Ther. 289 1999 1271 1276
56. M. Pattarawarapan, and K. Burgess Molecular basis of neurotrophin- receptor interactions J. Med. Chem. 46 2003 5277 5291
57. S. Paul Steven Paul Nat. Rev. Drug Discov. 8 2009 14
58. S.M. Paul, D.S. Mytelka, C.T. Dunwiddie, C.C. Persinger, B.H. Munos, S.R. Lindborg, and A.L. Schacht How to improve R&D productivity: the pharmaceutical industry's grand challenge Nat. Rev. Drug Discov. 9 2010 203 214
59. S. Pezet, and S.B. McMahon Neurotrophins: mediators and modulators of pain Annu. Rev. Neurosci. 29 2006 507 538
60. S.L. Rankin, C.S. Guy, and K.M. Mearow TrkA NGF receptor plays a role in the modulation of p75NTR expression Neurosci. Lett. 383 2005 305 310
61. R.C. Robinson, C. Radziejewski, G. Spraggon, J. Greenwald, M.R. Kostura, L.D. Burtnick, D.I. Stuart, S. Choe, and E.Y. Jones The structures of the neurotrophin 4 homodimer and the brain-derived neurotrophic factor/neurotrophin 4 heterodimer reveal a common Trk-binding site Protein Sci. 8 1999 2589 2597
62. R.C. Robinson, C. Radziejewski, D.I. Stuart, and E.Y. Jones Structure of the brain-derived neurotrophic factor/neurotrophin 3 heterodimer Biochemistry 34 1995 4139 4146
63. G.M. Ross, I.L. Shamovsky, G. Lawrance, M. Solc, S.M. Dostaler, S.L. Jimmo, D.F. Weaver, and R.J. Riopelle Zinc alters conformation and inhibits biological activities of nerve growth factor and related neurotrophins Nat. Med. 3 1997 872 878
64. G.M. Ross, I.L. Shamovsky, G. Lawrance, M. Solc, S.M. Dostaler, D.F. Weaver, and R.J. Riopelle Reciprocal modulation of TrkA and p75NTR affinity states is mediated by direct receptor interactions Eur. J. Neurosci. 10 1998 890 898
65. J. Scholz, and C.J. Woolf The neuropathic pain triad: neurons, immune cells and glia Nat. Neurosci. 10 2007 1361 1368
66. I.L. Shamovsky, G.M. Ross, R.J. Riopelle, and D.F. Weaver The interaction of neurotrophins with the p75NTR common neurotrophin receptor: a comprehensive molecular modeling study Protein Sci. 8 1999 2223 2233
67. P. Tapley, F. Lamballe, and M. Barbacid K252a is a selective inhibitor of the tyrosine protein kinase activity of the trk family of oncogenes and neurotrophin receptors Oncogene 7 1992 371 381
68. K.K. Teng, and B.L. Hempstead Neurotrophins and their receptors: signaling trios in complex biological systems Cell. Mol. Life Sci. 61 2004 35 48
69. M.H. Tuszynski, L. Thal, M. Pay, D.P. Salmon, H.S. U, R. Bakay, P. Patel, A. Blesch, H.L. Vahlsing, G. Ho, G. Tong, S.G. Potkin, J. Fallon, L. Hansen, E.J. Mufson, J.H. Kordower, C. Gall, and J. Conner A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease Nat. Med. 11 2005 551 555
70. M. Vilar, I. Charalampopoulos, R.S. Kenchappa, A. Simi, E. Karaca, A. Reversi, S. Choi, M. Bothwell, I. Mingarro, W.J. Friedman, G. Schiavo, P.I. Bastiaens, P.J. Verveer, B.D. Carter, and C.F. Ibanez Activation of the p75 neurotrophin receptor through conformational rearrangement of disulphide-linked receptor dimers Neuron 62 2009 72 83
71. A.D. Wasan, E.L. Ross, E. Michna, L. Chibnik, S.F. Greenfield, R.D. Weiss, and R.N. Jamison Craving of prescription opioids in patients with chronic pain: a longitudinal outcomes trial J. Pain 13 2012 148 156
72. J.J. Watson, S.J. Allen, and D. Dawbarn Targeting nerve growth factor in pain: what is the therapeutic potential? BioDrugs 22 2008 349 359
73. T. Wehrman, X. He, B. Raab, A. Dukipatti, H. Blau, and K.C. Garcia Structural and mechanistic insights into nerve growth factor interactions with the TrkA and p75 receptors Neuron 53 2007 25 38
74. C. Wiesmann, M.H. Ultsch, S.H. Bass, and A.M. de Vos Crystal structure of nerve growth factor in complex with the ligand-binding domain of the TrkA receptor Nature 401 1999 184 188
75. S.B. Woo, C. Whalen, and K.E. Neet Characterization of the recombinant extracellular domain of the neurotrophin receptor TrkA and its interaction with nerve growth factor (NGF) Protein Sci. 7 1998 1006 1016
76. C.J. Woolf Central sensitization: implications for the diagnosis and treatment of pain Pain 152 2011 S2 15
77. Y. Xie, and F.M. Longo Neurotrophin small-molecule mimetics Prog. Brain Res. 128 2000 333 347
78. Y. Xie, M.A. Tisi, T.T. Yeo, and F.M. Longo Nerve growth factor (NGF) loop 4 dimeric mimetics activate ERK and AKT and promote NGF-like neurotrophic effects J. Biol. Chem. 275 2000 29868 29874